Browsing Tag
GLP-1
37 posts
Are compounded weight-loss drugs the next opioid crisis? Inside the unregulated boom of off-label GLP-1s
Are GLP-1 weight-loss drugs like semaglutide fueling a new safety crisis? Explore the unregulated boom in compounded injections and FDA’s crackdown.
September 12, 2025
GLP-1 crackdown intensifies: What FDA’s new green list means for tirzepatide safety
The FDA’s new GLP-1 green list aims to block illegal semaglutide and tirzepatide imports. Find out how it could reshape the compounding pharmacy landscape.
September 7, 2025
Novo Nordisk stock rises on Wegovy STEER data: Can semaglutide cement its lead over Eli Lilly?
Novo Nordisk shares gained after STEER study showed Wegovy cut heart risks by 57% over tirzepatide. Find out why semaglutide may lead the GLP-1 race.
September 1, 2025
Is protein personalization the next frontier in sports nutrition and metabolic health?
Explore how personalized protein blends are transforming sports nutrition and metabolic health by 2027. Learn about biomarker-driven customization, market growth, and investor moves.
July 2, 2025
OrsoBio unveils ADA 2025 preclinical data showcasing dual-pathway obesity drug strategy with lean mass preservation
OrsoBio presents ADA 2025 data on TLC-6740 and TLC-1180 showing sustained fat loss and lean mass preservation in obesity models. Human trials underway.
June 25, 2025
How Novo Nordisk is building a post-semaglutide strategy: Inside its metabolic pipeline and innovation bets
Novo Nordisk pivots beyond semaglutide with amycretin, CagriSema, and oral GLP-1 therapies. See how it’s building its next-generation obesity drug platform.
June 24, 2025
Gan & Lee Pharmaceuticals reveals competitive Phase 2 results for bofanglutide and GZR4 at ADA 2025 sessions
Gan & Lee Pharmaceuticals presented strong Phase 2 results for bofanglutide and GZR4 in type 2 diabetes, advancing its long-acting diabetes pipeline.
June 21, 2025
Novo Nordisk advances amycretin to phase 3 after early data show weight loss of up to 24% in obesity trials
Novo Nordisk moves amycretin to phase 3 after early trials show up to 24% weight loss. See what makes this dual-receptor drug a next-gen obesity contender.
June 21, 2025
Novo Nordisk’s high-dose Wegovy delivers 21% weight loss in STEP UP Phase 3 trial results
Novo Nordisk’s high-dose Wegovy led to 21% weight loss in a Phase 3 trial. Learn what the STEP UP data means for obesity care and future regulatory plans.
June 21, 2025
Can Lilly’s flat $499/month Zepbound pricing reshape obesity drug access in the U.S.?
Lilly expands Zepbound access via LillyDirect, offering all FDA-approved doses for $499/month. Explore the implications for patients and the GLP-1 drug market.
June 17, 2025